See more : Citius Resources Plc (CRES.L) Income Statement Analysis – Financial Results
Complete financial analysis of TransMedics Group, Inc. (TMDX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of TransMedics Group, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
- Pila Pharma AB (publ) (PILA.ST) Income Statement Analysis – Financial Results
- Daisyo Corporation (9979.T) Income Statement Analysis – Financial Results
- Mersen S.A. (CBLNY) Income Statement Analysis – Financial Results
- Changhong Meiling Co., Ltd. (200521.SZ) Income Statement Analysis – Financial Results
- Coop Opsparing Moderat (COIMRA.CO) Income Statement Analysis – Financial Results
TransMedics Group, Inc. (TMDX)
About TransMedics Group, Inc.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 241.62M | 93.46M | 30.26M | 25.64M | 23.60M | 13.02M | 7.69M | 6.21M |
| Cost of Revenue | 87.53M | 28.19M | 9.10M | 9.00M | 9.74M | 7.28M | 5.55M | 5.44M |
| Gross Profit | 154.09M | 65.27M | 21.16M | 16.64M | 13.86M | 5.73M | 2.14M | 766.00K |
| Gross Profit Ratio | 63.77% | 69.84% | 69.92% | 64.88% | 58.73% | 44.05% | 27.81% | 12.34% |
| Research & Development | 63.27M | 26.81M | 22.30M | 18.83M | 19.87M | 13.66M | 14.96M | 15.64M |
| General & Administrative | 119.55M | 51.69M | 38.28M | 24.19M | 21.52M | 12.32M | 7.61M | 0.00 |
| Selling & Marketing | 0.00 | 18.21M | 8.60M | 931.00K | 2.07M | 1.02M | 674.00K | 0.00 |
| SG&A | 119.55M | 69.90M | 38.28M | 24.19M | 23.60M | 12.32M | 7.61M | 8.12M |
| Other Expenses | 0.00 | -1.00M | -877.00K | 1.65M | 790.00K | -213.00K | 548.00K | 5.00K |
| Operating Expenses | 182.82M | 96.71M | 60.59M | 43.02M | 43.47M | 25.97M | 22.56M | 23.75M |
| Cost & Expenses | 270.35M | 124.90M | 69.69M | 52.02M | 53.21M | 33.25M | 28.11M | 29.20M |
| Interest Income | 12.50M | 900.00K | 100.00K | 700.00K | 1.00M | 0.00 | 548.00K | 5.00K |
| Interest Expense | 10.79M | 3.73M | 3.87M | 3.99M | 4.35M | 2.42M | 1.07M | 979.00K |
| Depreciation & Amortization | 8.18M | 4.20M | 2.65M | 1.58M | 1.22M | 769.00K | 630.00K | 426.00K |
| EBITDA | -7.60M | -28.96M | -38.49M | -23.15M | -27.93M | -20.23M | -19.09M | -22.66M |
| EBITDA Ratio | -3.15% | -34.71% | -133.19% | -96.46% | -122.07% | -151.19% | -250.46% | -363.26% |
| Operating Income | -28.73M | -31.44M | -39.43M | -26.38M | -29.60M | -20.24M | -20.43M | -22.99M |
| Operating Income Ratio | -11.89% | -33.64% | -130.29% | -102.91% | -125.42% | -155.47% | -265.79% | -370.20% |
| Total Other Income/Expenses | 2.06M | -4.73M | -4.75M | -2.33M | -3.90M | -3.48M | -365.00K | -1.08M |
| Income Before Tax | -26.67M | -36.17M | -44.18M | -28.72M | -33.51M | -23.72M | -20.79M | -24.07M |
| Income Before Tax Ratio | -11.04% | -38.70% | -145.99% | -112.00% | -141.95% | -182.18% | -270.54% | -387.58% |
| Income Tax Expense | -1.64M | 66.00K | 36.00K | 32.00K | 40.00K | 41.00K | 32.00K | 984.00K |
| Net Income | -25.03M | -36.23M | -44.22M | -28.75M | -33.55M | -23.76M | -20.82M | -24.07M |
| Net Income Ratio | -10.36% | -38.77% | -146.11% | -112.13% | -142.12% | -182.50% | -270.96% | -387.58% |
| EPS | -0.77 | -1.23 | -1.60 | -1.16 | -2.36 | -1.23 | -1.44 | -1.66 |
| EPS Diluted | -0.77 | -1.23 | -1.60 | -1.16 | -2.36 | -1.23 | -1.44 | -1.66 |
| Weighted Avg Shares Out | 32.52M | 29.56M | 27.62M | 24.70M | 14.20M | 19.25M | 14.48M | 14.48M |
| Weighted Avg Shares Out (Dil) | 32.52M | 29.56M | 27.62M | 24.70M | 14.20M | 19.25M | 14.48M | 14.48M |
TransMedics Group: Providing Long-Term Detailed Forecast And Upgrading To Buy
New Strong Buy Stocks for August 2nd
Compared to Estimates, TransMedics (TMDX) Q2 Earnings: A Look at Key Metrics
Why TransMedics Group Stock Is Soaring Today
TransMedics Group Raises Full-Year Guidance
TransMedics Group, Inc. (TMDX) Q2 2024 Earnings Call Transcript
TransMedics (TMDX) Q2 Earnings and Revenues Top Estimates
TransMedics Reports Second Quarter 2024 Financial Results
TransMedics to Present at the Canaccord Genuity 44th Annual Growth Conference
Wall Street's Insights Into Key Metrics Ahead of TransMedics (TMDX) Q2 Earnings
Source: https://incomestatements.info
Category: Stock Reports